Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2938-2946

  Lewis, Jennifer D ^a   Shearer, Michael H ^a   Kennedy, Ronald C ^a   Bright, Robert K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BREAST CARCINOMA; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNIZATION; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; T-LYMPHOCYTES;

EID: 16844380277     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2874     Document Type: Article

References (41)

1. Bright RK, Jumper CA. Immunotherapy. In: Pass HI, Carbone DP, Johnson DH, Minna JD, Turrisi III AT, editors. Lung cancer: principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
2. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.
3. Lewis JD, Reilly BD, Bright RK. Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 2003;22:81-112.
4. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
5. Pulaski B, Ostrand-Rosenberg S. MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth. Cancer Res 1998;58:1486-93.
6. Coveney E, Wheatley GH, Lyerly HK. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery 1997;122:228-34.
7. + tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced interferon γ. Cancer Immunol Immunother 2000;49:34-45.
8. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-7.
9. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993;14:203-8.
10. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003;24:58-61.
11. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated disease: implications for immunotherapy. Nat Rev Immunol 2002;21:85-95.
12. Sercarz EE. Driver clones and determinant spreading. J Autoimmun 2000;14:275-7.
13. El-Shami K, Tirosh B, Bar-Haim E, et al. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 1999;29:3295-301.
14. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 2001;13:625-32.
15. Lanford RE. Expression of simian virus 40 T antigen in insect cells using a baculovirus expression vector. Virology 1988;167:72-81.
16. Shearer MH, Lanford RL, Kennedy RC. Monoclonal anti-idiotypic antibodies induce humoral immune responses specific for simian virus 40 large tumor antigen in mice. J Immunol 1990;145:932-9.
17. Kit ST, Kurimura T, Dubbs DR. Transplantable mouse tumor line induced by injection of SV40-transformed mouse kidney cells. Int J Cancer 1969;4:384-92.
18. Bright RK, Shearer MH, Pass HI, Kennedy RC. Immunotherapy of SV40-induced tumors in mice: a model for vaccine development. Dev Biol Stand 1998;94:341-53.
19. Bright RK, Kimchi ET, Shearer MH, Kennedy RC, Pass HI. SV40 tag specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients. Cancer Immunol Immunother 2002;50:682-90.
20. Bright RK, Shearer MH, Kennedy RC. SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice. Mol Immunol 1994;14:1077-87.
21. Bright RK, Shearer MH, Kennedy RC. Fine specificity of the murine immune response to SV40 large tumour antigen utilizing synthetic peptides that define selected epitopes. Clin Exp Immunol 1994;96:491-9.
22. Bright RK, Shearer MH, Kennedy RC. Comparison of the murine humoral immune response to recombinant simian virus 40 large tumor antigen: epitope specificity and idiotype expression. Cancer Immunol Immunother 1993;37:31-9.
23. Shearer MH, Bright RK, Kennedy RC. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype. Cancer Res 1993;53:5734-9.
24. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-8.
25. Heath WH, Carbone FR. Cross-presentation, dendritic cells, tolerance, and immunity. Annu Rev Immunol 2001;19:47-64.
26. Huang AY, Golumbek P, Ahmadzedah M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC I-restricted tumor antigens. Science 1994;264:961-5.
27. Bright RK, Beames B, Shearer MH, Kennedy RC. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res 1996;56:1126-30.
28. Bright RK, Shearer MH, Kennedy RC. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody based mechanism for tumor immunity. J Immunol 1994;153:2064-71.
29. + lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res 2003;63:1040-5.
30. Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK. Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines. Adv Exp Med Biol 1998;451:259-64.
31. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang N-S. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000;1:826-38.
32. Prigozhina TB, Gurevitch O, Morecki S, Yahovlev E, Elkin G, Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002;30:89-96.
33. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperatively of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and DC80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60:2710-5.
34. Ostrand-Rosenberg S, Grusby MJ, Clements VK. STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 2000;165:6015-9.
35. Bauminger S, Yachnin S. Unimpeded growth of tumour in hosts pre-immunized with tyrosyl- or dinithrophenyl-coated tumor cells. Br J Cancer 1972;26:77-83.
36. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996;93:15388-93.
37. Kobayashi H, Sendo F, Shirai T Kaji H, Kodama T. Modification in growth of transplantable rat tumors exposed to friend virus. J Natl Cancer Inst 1969;42:413-9.
38. Kobayashi H, Gotohda E, Hosokawa M, Kodama J. Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor. J Natl Cancer Inst 1975;54:997-9.
39. Van Pel A, Boon T. Protection against a non-immunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A 1982;79:4718-22.
40. + T cell responses provide evidence of in vivo cross-presentation by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
41. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cells. J Immunother 2001;24:163-71.